Endo International Plc reported fall in Revenue in the fourth quarter 2023 by -10.45% to $ 497.73 millions, from the same quarter in 2022. The decline in the fourth quarter 2023 Endo International Plc's Revenue compares unfavorably to the Company's average Revenue decrease of -6.66%.
Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Revenue growth. While Endo International Plc' s Revenue decrease of -10.45% ranks overall at the positon no. 1961 in the fourth quarter 2023.
ENDPQ Revenue ( Y/Y Growth %)
2023
2022
2021
2020
4th Quarter
December
-10.45 %
-29.59 %
3.84 %
-0.6 %
3rd Quarter
September
-16.62 %
-29.84 %
21.61 %
-12.96 %
2nd Quarter
June
-3.91 %
-20.27 %
3.82 %
-1.73 %
1st Quarter
March
-21 %
-9.15 %
-12.49 %
13.88 %
FY
-13.25 %
-22.53 %
3.1 %
-
Financial Statements
Endo International Plc's fourth quarter 2023 Revenue
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023
Endo International Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
20.87 %
-3.97 %
-100 %
(Jun 30 2014)
ENDPQ's IV. Quarter Q/Q Revenue Comment
Endo International Plc achieved in the IV. Quarter 2023 above company average sequential Revenue rise of 10.2%, to $ 497.73 millions, from $451.67 millions in the third quarter. ENDPQ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Revenue quarter on quarter growth. While Endo International Plc's Revenue growth quarter on quarter, overall rank is 952.
Endo International Plc achieved in the IV. Quarter 2023 above company average sequential Revenue rise of 10.2%, to $ 497.73 millions, from $451.67 millions in the third quarter. ENDPQ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Revenue quarter on quarter growth. While Endo International Plc's Revenue growth quarter on quarter, overall rank is 952.
Endo International Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Dec 31 2023)
12 Months Ending (Sep 30 2023)
12 Months Ending (Jun 30 2023)
12 Months Ending (Mar 31 2023)
12 Months Ending (Dec 31 2022)
Cumulative Revenue 12 Months Ending
$ 2,011.52
$ 2,069.60
$ 2,159.62
$ 2,181.88
$ 2,318.88
Y / Y Revenue Growth (TTM)
-13.25 %
-18.92 %
-22.39 %
-25.47 %
-22.53 %
Year on Year Revenue Growth Overall
Ranking
# 3439
# 2989
# 1700
# 1169
# 1866
Seqeuential Revenue Change (TTM)
-2.81 %
-4.17 %
-1.02 %
-5.91 %
-9.15 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2924
# 2741
# 2834
# 2715
# 1979
Cumulative Revenue growth Comment
Endo International Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Endo International Plc's annual Revenue decrease would be -13.25% year on year to $2,012 millions.
In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2989 to 3439.
Endo International Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Endo International Plc's annual Revenue drop would be -13.25% year on year to $2,012 millions.
In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2989 to 3439.
About Endo International Plc Revenue Growth Rates (ENDPQ), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
